期刊文献+

HPLC法测定磷酸西格列汀的含量 被引量:4

Determination of Sitagliptin Phosphate Contents by HPLC
下载PDF
导出
摘要 采用HPLC法测定磷酸西格列汀的含量.方法:采用C18(4.6 mm×215;250 mm,5μm)色谱柱,以0.01 mol/L磷酸氢二钠溶液(用磷酸调节pH至6.8)∶乙腈=60∶40为流动相,流速为1.0 mL/min,检测波长为220 nm,柱温为30℃.结果:磷酸西格列汀的线性范围为0.2300~0.3942mg/mL;结论:本法简便、准确、适合于磷酸西格列汀含量测定. To establish an HPLC method for quantitative determination of Sitagliptin phosphate. Methods: The analytical column was C18 (4.6 mm×250 mm, 5 μm) cohmm. The mobile phase was 0.01 mol/L disodium hydrogen phosphate aqueous solution (phosphoric acid to adjust to pH 6.8) and acetonitrile (60 : 40) at a flow rate of 1.0 mL/min. The wavelength of UV detector was 220 nm and column temperature was 30℃. Results: The linear ranges of Sitagliptin phosphate were 0.2300-0.3942 mg/ml Conclusion: The method is simple, accurate and suitable for the content determination of Sitagliptin phosphate,
作者 计莹 韩凤云
出处 《广东化工》 CAS 2014年第23期204-204,共1页 Guangdong Chemical Industry
关键词 磷酸西格列汀 HPLC法 含量测定 sitagliptin phosphate HPLC method content determination
  • 相关文献

参考文献4

二级参考文献75

  • 1Matsuyama-Yokono A, Tahara A, Nakano R, et al. Antidiabetic effects of dipeptidyl peptidase-4 inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice[J]. Metabolism, 2009, 58(3): 379-386.
  • 2Deacon CF, Hoist JJ. Dipeptidyl peptidase-4inhibitors: a promising new therapeutic approach for the management of type 2 diabetes[J]. Int J Biochem Cell Biol, 2006, 38(526): 831-844.
  • 3Azuma K, Radikova Z, Mancino J, et al. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes[J]. J Clin Endocrinol Metab, 2008, 93( 2): 459-464.
  • 4Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes[J]. Diabetes Obes Metab, 2008, 10(5): 376-386.
  • 5Garcia-Soria G, Gonzalez-Galvez G, Argoud GM, et al. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2008, 10( 4): 293-300.
  • 6Deacon CF. Circulation and degradation of GIP and GLP-1 [J]. Horm Metab Res, 2004, 36 (11-12): 761-765.
  • 7Mentlein R. Dipeptidyl-peptidase 4(CD26)-role in the inactivation of regulatory peptides[J]. Regul Pept, 1999, 85(1): 9-24.
  • 8赵耀.荚国辉瑞授予SatRx公司糖尿病新药PF-00734200销售权[EB/OL].(2012-07-09)[2012-07-25].http://overseas.caijing.tom.cn/2012-07-09/111936901.html.
  • 9徐瑾妍.日药商Astellas40亿美元收购美生物技术公司OSI[EB/OL].(2010-05-17)[2012-06-27].http:/mnancejrj.corn.cn/biz/2010/05/1711077474385.shtml.
  • 10永达.日本田边三菱与第一三共公司签订销售合同[EB/OL].(2012-03-12)[2012-07-28].http://info.yup.cn/medicine/47238.jhtml.

共引文献33

同被引文献10

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部